Evolus (EOLS) to Release Quarterly Earnings on Wednesday

Evolus (NASDAQ:EOLS - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data after the market closes on Wednesday, May 7th. Analysts expect Evolus to post earnings of ($0.04) per share and revenue of $73.06 million for the quarter.

Evolus Stock Up 2.4 %

Shares of EOLS stock traded up $0.28 on Friday, hitting $12.08. The stock had a trading volume of 957,476 shares, compared to its average volume of 666,727. The stock's 50 day moving average is $11.98 and its 200-day moving average is $12.77. The firm has a market capitalization of $778.81 million, a price-to-earnings ratio of -13.27 and a beta of 1.11. Evolus has a 52-week low of $8.67 and a 52-week high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Analysts Set New Price Targets

Several analysts have recently weighed in on EOLS shares. BTIG Research began coverage on Evolus in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 target price for the company. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Evolus in a report on Wednesday, April 9th. Barclays increased their target price on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Finally, HC Wainwright restated a "buy" rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $23.75.

Insiders Place Their Bets

In other Evolus news, CFO Sandra Beaver sold 8,996 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $119,286.96. Following the transaction, the chief financial officer now owns 173,583 shares of the company's stock, valued at $2,301,710.58. This trade represents a 4.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Rui Avelar sold 27,904 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the transaction, the insider now directly owns 362,467 shares of the company's stock, valued at $4,806,312.42. This trade represents a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 60,575 shares of company stock valued at $794,369 in the last quarter. Insiders own 6.10% of the company's stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.